Biomarin Pharmaceutical Inc (BMRN) – aksjekurser og nyheter

BMRN:NASDAQ

Biomarin Pharmaceutical Inc

59,00 USD

+2,88%

(+1,65) 1 D

58,60 USD

−0,68% (−0,40)

Etter stengetid

Stengt: 26. juni, 16:00:02 GMT-4 · USD

Alle symboler

1 D

5 D

1 M

6 M

I år

1 Å

5 Å

MAKS

	Symbol	Pris	Endring	Endring (%)

Genererer viktig statistikk for BMRN …

Åpne

57,35 USD

Høy

59,77 USD

Lav

57,35 USD

Markedsverdi

11,40 mrd.

Snittvolum

2,37 mill.

Volum

3,71 mill.

P/E-forhold

43,05

52 u høy

66,28 USD

52 u lav

49,26 USD

EPS

1,37 USD

Beta

0,25

Utestående aksjer

193,28 mill.

Antall ansatte

Åpne

57,35 USD

Høy

59,77 USD

Lav

57,35 USD

Markedsverdi

11,40 mrd.

Snittvolum

2,37 mill.

Volum

3,71 mill.

P/E-forhold

43,05

52 u høy

66,28 USD

52 u lav

49,26 USD

EPS

1,37 USD

Beta

0,25

Utestående aksjer

193,28 mill.

Antall ansatte

Relaterte aksjer

RVMD

Revolution Medicines Inc

182,08 USD

+2,19%

VRTX

Vertex Pharmaceuticals Inc

Nyhetssaker

Fra kilder på nettet

Simply Wall Street

for 3 timer siden

BioMarin Pharmaceutical (BMRN) Highlights ENDO 2026 Progress, Is The Stock Undervalued?

Ad-hoc-news.de

for 2 døgn siden

BioMarin Pharmaceutical, Friday analyst angle, shares in focus

Profil

BioMarin Pharmaceutical Inc. is an American biotechnology company headquartered in San Rafael, California. It has offices and facilities in the United States, South America, Asia, and Europe. BioMarin's core business and research are in enzyme replacement therapies. BioMarin was the first company to provide therapeutics for mucopolysaccharidosis type I, by manufacturing laronidase. BioMarin was also the first company to provide therapeutics for phenylketonuria. Over the years, BioMarin has been criticised for drug pricing and for specific instances of denying access to drugs in clinical trials. Wikipedia

Om Biomarin Pharmaceutical Inc

Administrerende direktørAlexander Hardy

Ansatte3,22k

Grunnlagtmars 1997

HovedkontorSan Rafael, California, USA

Sektor-

Nettstedbiomarin.com

Analytikervurderinger

Basert på 20 analytikere som har gitt aksjevurderinger for BMRN de siste 3 månedene

Sterkt kjøp

Kjøp

Vent

Selg

12-månedersprognose

Basert på 20 Wall Street-analytikere som har gitt 12-måneders prismål for BMRN de siste 3 månedene.

Høyest

Gjeldende 59,00 USD

120,00 USD (+103,39%)

Gjennomsnittlig

87,00 USD (+47,46%)

Lavest

50,00 USD (−15,25%)

Analytiker	Anbefaling	Handling	Prismål	Anslått	Dato
Mitchell Kapoor H.C. Wainwright	Hold	Reiterated	50,00 USD	−15,3%	06/22/2026
Unknown Analyst Guggenheim	Buy	Maintained	86,00 USD	+45,8%	06/03/2026
Jason Gerberry Bank of America Securities	Buy	Reiterated	80,00 USD	+35,6%	05/29/2026
Paul Matteis Stifel Nicolaus	Hold	Maintained	68,00 USD	+15,3%	05/24/2026
Whitney Ijem Canaccord Genuity	Buy	Maintained	111,00 USD	+88,1%	05/22/2026
Christopher Raymond Raymond James	Buy	Maintained	-	-	05/22/2026
Akash Tewari Jefferies	Buy	Maintained	104,00 USD	+76,3%	05/21/2026
Cory Kasimov Evercore ISI	Buy	Maintained	120,00 USD	+103,4%	05/21/2026
Allison Bratzel Piper Sandler	Buy	Maintained	82,00 USD	+39%	05/21/2026
Yun Zhong Wedbush	Buy	Reiterated	94,00 USD	+59,3%	05/21/2026
Phil Nadeau TD Cowen	Buy	Maintained	120,00 USD	+103,4%	05/21/2026
Eric Joseph Citi	Buy	Maintained	80,00 USD	+35,6%	05/20/2026
Unknown Analyst J.P. Morgan	Buy	Maintained	80,00 USD	+35,6%	05/20/2026
Mohit Bansal Wells Fargo	Buy	Reiterated	75,00 USD	+27,1%	05/21/2026
Jason Zemansky Bank of America Securities	Buy	Maintained	80,00 USD	+35,6%	05/19/2026
Eliana Merle Barclays	Buy	Reiterated	105,00 USD	+78%	05/21/2026
Unknown Analyst Citi	Buy	Initiated	-	-	05/19/2026
Joseph Schwartz Leerink Partners	Hold	Reiterated	62,00 USD	+5,1%	05/18/2026
Salveen Richter Goldman Sachs	Hold	Initiated	69,00 USD	+16,9%	05/11/2026
Luca Issi RBC Capital	Hold	Maintained	66,00 USD	+11,9%	05/04/2026
William Pickering Bernstein	Buy	Reiterated	82,00 USD	+39%	05/05/2026
Sean Laaman Morgan Stanley	Buy	Reiterated	119,00 USD	+101,7%	05/06/2026
Joon Lee Truist Financial	Buy	Maintained	-	-	03/03/2026
Olivia Brayer Cantor Fitzgerald	Buy	Maintained	85,00 USD	+44,1%	03/02/2026
Sami Corwin William Blair	Hold	Maintained	-	-	02/24/2026

Alle verdier i USD	juni 2025	sep. 2025	des. 2025	mars 2026
Inntekt	825,41 mill.	776,13 mill.	874,56 mill.	766,21 mill.
Varekostnad	311,40 mill.	549,56 mill.	348,91 mill.	373,80 mill.
Direkte driftskostnader	311,40 mill.	549,56 mill.	348,91 mill.	373,80 mill.
Utgifter til forskning og utvikling	-	-	-	-
Totale kostnader til forskning og utvikling	-	-	-	-
Salgskostnader, generelle kostnader og administrative kostnader	232,28 mill.	268,42 mill.	324,16 mill.	249,98 mill.
Driftskostnader	237,12 mill.	273,26 mill.	329,01 mill.	254,46 mill.
Totale driftskostnader	548,52 mill.	822,82 mill.	677,92 mill.	628,26 mill.
Driftsinntekter	276,89 mill.	−46,69 mill.	196,64 mill.	137,95 mill.
Andre ikke-operasjonelle inntekter	4,83 mill.	5,09 mill.	1,02 mill.	3,96 mill.
EBT inkludert uvanlige elementer	297,87 mill.	−26,32 mill.	−27,15 mill.	141,20 mill.
EBT uten uvanlige elementer	297,87 mill.	−26,32 mill.	214,10 mill.	149,52 mill.
Kostnad for inntektsskatt	57,34 mill.	4,42 mill.	19,42 mill.	35,68 mill.
Faktisk avgiftssats	19,25 %	−16,79 %	−71,52 %	25,27 %
Andre driftskostnader	-	-	-	-
Nettoinntekt	240,53 mill.	−30,74 mill.	−46,57 mill.	105,53 mill.
Netto fortjenestemargin	29,14 %	−3,96 %	−5,33 %	13,77 %
Resultat per aksje	1,44	0,12	0,46	0,76
Rente- og investeringsinntekter	18,83 mill.	17,85 mill.	19,21 mill.	22,56 mill.
Rentekostnader	−2,68 mill.	−2,58 mill.	−2,78 mill.	−14,96 mill.
Netto rentekostnader	16,15 mill.	15,28 mill.	16,43 mill.	7,60 mill.
Avskrivnings- og amortiseringskostnader	-	-	-	-
EBITDA	295,45 mill.	−28,20 mill.	209,68 mill.	154,36 mill.
Gevinst eller tap ved salg av eiendeler	-	-	-	-

AI-innhold kan inneholde feil. Finn ut mer

HjelpSend tilbakemeldingPersonvern Vilkår Ansvarsfraskrivelse

Finance

Utforskning